WuXi Biologics, a contract research, development and manufacturing organization (CRDMO), unveiled a 10-year $1.4 billion investment plan to expand the company’s research, development and large-scale drug substance and drug product (DS/DP) manufacturing capacity and capabilities in Singapore. This new site will add 120,000L biomanufacturing capacity to WuXi Biologics’ global network by 2026 and is anticipated to employ 1,500 research, development and manufacturing staff when complete.

Following the momentum of continued investments in the U.S., Ireland, Germany and China, this new addition in Singapore will become a critical part of the robust global supply chain network WuXi Biologics has established to fully meet the needs of global clients. The center will also reinforce WuXi Biologics’ Global Dual Sourcing strategy, which ensures that customer projects can be fulfilled at multiple facilities globally to mitigate potential risks.

WuXi Biologics’ investment plan is supported by the Singapore Economic Development Board (EDB). “We warmly welcome WuXi Bio’s plan,” said Beh Swan Gin, chairman of EDB. “The investments will establish Singapore as a significant node in the company’s global research, development and manufacturing network. It is a testament to Singapore’s position as a global biopharmaceutical hub, and will strengthen our attractiveness to biotech innovators and start-ups.”

Chris Chen, CEO of WuXi Biologics, said, “Singapore has established itself as one of the most advanced pharmaceutical hubs in the world. As a trusted partner to global healthcare companies and a strong contributor to the local community, WuXi Biologics’ investment in the new CRDMO center will enhance the sustainable growth and success of the Singapore biotech ecosystem and enable the global biologics industry with a more robust supply chain. With the support of EDB and our local partners in Singapore, WuXi Biologics looks forward to moving ahead with this important project to enable global partners and benefit patients worldwide.”